GeneDx Holdings Corp.

GeneDx Holdings Corp. (Nasdaq: WGS) is a genomic diagnostics company that provides exome and genome sequencing tests for the diagnosis of rare genetic diseases. The company's mission centers on empowering patients to live healthier lives through genomics by combining clinical expertise, advanced technology, and proprietary datasets to deliver precise, fast, and actionable diagnoses to clinicians.

Founded in 2000 by scientists from the National Institutes of Health, GeneDx pioneered commercial next-generation sequencing panels in 2008 and exome sequencing in 2012. The company operates through its core diagnostic testing business, which generated substantially all revenue during the fiscal year ended December 31, 2025. GeneDx's primary products include the ExomeDx and GenomeDx tests, which have received FDA Breakthrough Device Designation and are ranked number one by expert geneticists. The company also offers rapid and ultrarapid genome sequencing options and genomic newborn screening protocols.

The company's competitive moat derives from GeneDx Infinity, one of the world's largest rare disease datasets, powered by data from over 2.5 million tests including more than one million exomes and genomes. This dataset is supplemented with more than eight million phenotypic datapoints and billions of longitudinal patient, clinical, and claims data points. Notably, more than fifty percent of the exomes and genomes represent individuals of non-European descent, providing diverse population representation. The company employs over one hundred medical doctors and PhDs and one hundred fifty genetic counselors who curate gene-disease knowledge and interpret results.

GeneDx operates a CLIA-certified laboratory in Gaithersburg, Maryland, and maintains state laboratory licenses in New York, California, Pennsylvania, and Rhode Island. The company employs approximately 1,300 individuals and maintains field-based sales and medical science liaison teams to expand adoption of exome and genome testing beyond specialist geneticists into pediatric and general medicine settings.

In May 2025, GeneDx acquired Fabric Genomics, a company that enhances the company's international expansion capabilities and artificial intelligence-powered variant interpretation tools. The company targets a combined market opportunity of approximately forty-five billion dollars across pediatric rare disease and adult disease diagnostics, with longer-term expansion into newborn screening and biopharma partnerships. More information is available at www.genedx.com.